Skip to content

Music therapy for delirium in advanced cancer patients. A randomized controlled trial.

Music therapy for delirium in advanced cancer patients. A randomized controlled trial. - MUT-Delir

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00040154
Enrollment
142
Registered
2026-05-18
Start date
2026-05-26
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F05

Interventions

Group 1: Intervention group: individualized music therapy (2 sessions of 40–60 minutes each, 2 days apart) Group 2: Control group (placebo treatment): attention control visits (including supportive pr

Sponsors

TUM Klinikum Rechts der Isar
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - patients aged 18 years or older - with a diagnosis of advanced cancer - inpatients receiving specialized palliative care (on the palliative care unit or through the palliative care service) at the TUM University Hospital - with delirium symptoms (as confirmed by a positive CAM-short assessment)

Exclusion criteria

Exclusion criteria: -patients with delirium tremens/alcohol withdrawal delirium - severe hearing impairment that cannot be corrected with a hearing aid - deafness - patients in the immediate process of dying

Design outcomes

Primary

MeasureTime frame
Delirium severity (as measured by the Delirium-O-Meter score) within 24 hours of the first session

Secondary

MeasureTime frame
Heart rate variability (measured using an optical heart rate sensor at 30-minute intervals before and immediately after the session) Agitation (assessed using the Richmond Agitation-Sedation Scale) Anxiety and well-being (assessed using the Edmonton Symptom Assessment Scale) delirium distress (NRS item, adapted from Bruera et al. 2009) Proportion of days with delirium symptoms (defined as the proportion of days during the study period with a positive CAM-short score) Use of benzodiazepines or neuroleptics between the first session and study end Acceptance/acceptability of the intervention

Countries

Germany

Contacts

Public ContactJohanna Anneser

TUM Klinikum Rechts der Isar

j.anneser@tum.de+49 89/4140-7611

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026